和元生物技術(shù)（上海）股份有限公司（股票代碼：688238）成立于2013年，是一家聚焦基因治療領(lǐng)域的生物科技公司，專注于為基因治療的基礎(chǔ)研究提供基因治療載體研制、基因功能研究、藥物靶點及藥效研究等CRO服務(wù)，為基因藥物的研發(fā)提供工藝開發(fā)及測試、IND-CMC藥學(xué)研究、臨床樣品GMP生產(chǎn)等CDMO服務(wù)。公司以“賦能基因治療，共守生命健康”為使命，圍繞病毒載體研發(fā)和大規(guī)模生產(chǎn)工藝開發(fā)，打造了基因治療載體開發(fā)技術(shù)；基因治療載體生產(chǎn)工藝及質(zhì)控技術(shù)兩大核心技術(shù)集群，建立了適用于多種基因藥物的大規(guī)模、高靈活性GMP生產(chǎn)體系，向基因治療領(lǐng)域提供：①質(zhì)粒、腺相關(guān)病毒、慢病毒等載體產(chǎn)品；②溶瘤皰疹病毒、溶瘤痘病毒等多種溶瘤病毒產(chǎn)品；③CAR-T、CAR-NK等細(xì)胞治療產(chǎn)品；④mRNA等其他產(chǎn)品的技術(shù)研究、工藝開發(fā)和GMP生產(chǎn)服務(wù)。基于公司自主搭建的分子生物學(xué)平臺、實驗級病毒載體包裝平臺、細(xì)胞功能研究平臺、SPF級動物實驗平臺、臨床級基因治療載體和細(xì)胞治療工藝開發(fā)平臺、質(zhì)控技術(shù)研究平臺等全面的技術(shù)平臺，依托公司已有的近5000平米研發(fā)中心、超10000平方米基因治療載體GMP生產(chǎn)中心，以及在上海自由貿(mào)易試驗區(qū)臨港新片區(qū)建設(shè)中的77,000平方米精準(zhǔn)醫(yī)療產(chǎn)業(yè)基地，公司將堅持以客戶為中心、以提供專業(yè)服務(wù)為己任，打造國際領(lǐng)先的基因和細(xì)胞治療CXO集團(tuán)企業(yè)，加快基因治療的基礎(chǔ)研究、藥物發(fā)現(xiàn)、藥學(xué)研究、臨床和商業(yè)化進(jìn)程，推動基因治療行業(yè)發(fā)展，造福人類健康！Founded in 2013 and headquartered in Shanghai, OBiO is a biotechnology company focusing on gene and cell therapy field: serving as a contract research organization for vectorology and functional genomics studies and providing contract development and manufacturing services of IND-enabling CMC, clinical and commercial manufacturing. In recent years, in line with the mission of enabling gene therapy for better lives, OBiO has established core technologies around vectorology development, large-scale process development and manufacturing, facilitating a robust and versatile GMP manufacturing system for various gene and cell therapy products.We leverage the core technologies in vectorology research and large-scale manufacturing, persistently facilitating the discovery, research, clinical study and commercialization of gene and cell therapy products. Based in Shanghai, we offer a wide range of services to global customers, aiming to bring benefit to the whole world with on our technology platform.